Please find attached Press Release
Filed with NSE · ISIN INE901L01018 · · 3 pages · English
Summary by 6ix AI
Alembic Pharmaceuticals Limited has announced an expansion of its strategic collaboration with DifGen Pharmaceuticals to enhance its complex generics portfolio in the US. The collaboration will leverage DifGen’s development and manufacturing capabilities alongside Alembic’s US commercial platform. Key highlights include a broad portfolio of differentiated products and near-term revenue visibility from initial launches expected in the near future. Managing Director Pranav Amin emphasized the collaboration's potential to deepen Alembic's pipeline and strengthen its US business growth.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Alembic Pharmaceuticals Limited on 6ix
In the deck
Earlier from Alembic Pharmaceuticals
- Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 04, 2026, titled "Press Release on the Unaudited Financial Results for the quarter and half year ended 30th September, 2026".
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Venetoclax Tablets, 10 mg, 50 mg and 100 mg.
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Valganciclovir for Oral Solution, 50 mg/mL.
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%.
- Alembic Pharmaceuticals Limited Press Release Aug 04 2026
Follow Alembic Pharmaceuticals into a list and get an email when it puts out news.
Follow Alembic Pharmaceuticals